DarioHealth (NASDAQ:DRIO – Get Free Report) and Nyxoah (NASDAQ:NYXH – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.
Volatility and Risk
DarioHealth has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500.
Institutional & Insider Ownership
33.4% of DarioHealth shares are owned by institutional investors. 16.5% of DarioHealth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DarioHealth | 0 | 0 | 1 | 0 | 3.00 |
| Nyxoah | 0 | 0 | 5 | 0 | 3.00 |
DarioHealth currently has a consensus price target of $4.00, indicating a potential upside of 476.37%. Nyxoah has a consensus price target of $17.00, indicating a potential upside of 55.82%. Given DarioHealth’s higher possible upside, equities analysts plainly believe DarioHealth is more favorable than Nyxoah.
Profitability
This table compares DarioHealth and Nyxoah’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DarioHealth | -205.62% | -72.16% | -40.74% |
| Nyxoah | -1,043.93% | -51.68% | -40.11% |
Valuation & Earnings
This table compares DarioHealth and Nyxoah”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DarioHealth | $20.35 million | 1.16 | -$59.43 million | ($0.94) | -0.74 |
| Nyxoah | $4.70 million | N/A | -$46.77 million | ($1.87) | -5.83 |
Nyxoah has lower revenue, but higher earnings than DarioHealth. Nyxoah is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.
Summary
DarioHealth beats Nyxoah on 8 of the 12 factors compared between the two stocks.
About DarioHealth
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.
